Oklo (OKLO) Q3 2024 earnings summary

Executive summary

• Achieved significant regulatory, project, and customer milestones in Q3 2024, including new agreements, licensing progress, and a strategic acquisition to expand into radioisotope production.

• Customer pipeline expanded to 2.1 GW of signed and non-binding agreements, with strong demand from data centers and diversified sectors.

• Announced $25 million all-stock acquisition of Atomic Alchemy, expected to close in early 2025, to integrate radioisotope production and enhance fuel recycling capabilities.

• Completed business combination with AltC in May 2024, raising $276.2 million gross and listing on NYSE.

• Well-capitalized balance sheet and disciplined cash management position the company for sustainable growth.

Financial highlights

• Year-to-date cash used in operating activities was $24.9 million, with a net loss of $63.3 million, including $38.5 million in non-cash impacts and $10.8 million in stock-based compensation.

• Operating loss for the nine months ended September 30, 2024, was $37.4 million, including a one-time $7.8 million fair value adjustment for earn-out shares.

• Cash, cash equivalents, and marketable securities totaled $288.5 million at quarter end, primarily from $276 million in deal closure proceeds.

• Full-year 2024 operating loss expected to be $40–$50 million, in line with prior guidance.

• Net loss for Q3 2024 was $9.96 million, up 14.9% year-over-year.

Outlook and guidance

• Targeting initial operations of the first plant in late 2027, with groundbreaking as soon as 2026 at the Idaho site.

• Combined License Application for Idaho project to be submitted next year, with subsequent applications following closely.

• Full-year 2024 financial expectations remain in line with prior guidance, with existing liquidity expected to fund operations for at least one year post-report date.

• Focused on building high-quality, long-term partnerships and integrating radioisotope production.

• Anticipates accelerated licensing for subsequent plants, potentially reducing review times to as little as seven months.